BACKGROUND: The aim of this study was to investigate whether human mast cells express functional active CCR3 receptors, which are activated by CC chemokines. These ligands include the CCR3-selective chemokines eotaxin and eotaxin-2 and the more promiscuous CC chemokines, MCP-4, MCP-3, MCP-2 and RANTES. METHODS: Immunohistochemical analysis was performed on skin, gut and lung specimens. Double immunostaining was performed with anti-CCR3 and antitryptase, and anti-CCR3 and antichymase antibody (Ab) by using the avidin-biotin-peroxidase system with two different substrates. Mast cells were isolated and purified from human lung parenchyma (HLMC) by countercurrent elutriation followed by discontinuous Percoll density gradient. Flow-cytometric analysis of HLMC surface CCR3 expression was performed with the monoclonal Ab anti-CCR3 (7B11). Functional activation of HLMC was verified by the ability of cells to release histamine and/or migrate in response to eotaxin. RESULTS: High percentages (>70%) of tryptase-positive cells showing CCR3 expression were found in the skin and in the intestinal submucosa, whereas much lower percentages (< or = 20%) were found in the intestinal mucosa and in the lung interstitium. Eotaxin (1-100 nM) neither induced histamine release from HLMC nor enhanced anti-IgE-induced histamine release. In contrast, eotaxin (10-100 nM) and RANTES (10-100 nM) induced HLMC chemotaxis in vitro. Preincubation of HLMC with antibody anti-CCR3 (5 microg/ml) before loading into the chemotaxis chamber abrogated chemotaxis elicited by eotaxin. Double immunostaining with anti-CCR3 and anti-chymase antibody showed that the vast majority of CCR3-expressing mast cells in the various human tissues examined were tryptase-chymase double-positive. CONCLUSIONS: These results indicate that CCR3 is expressed on human mast cells and that these cells are attracted by CCR3-binding chemokines. Copyright 2001 S. Karger AG, Basel
BACKGROUND: The aim of this study was to investigate whether human mast cells express functional active CCR3 receptors, which are activated by CC chemokines. These ligands include the CCR3-selective chemokines eotaxin and eotaxin-2 and the more promiscuous CC chemokines, MCP-4, MCP-3, MCP-2 and RANTES. METHODS: Immunohistochemical analysis was performed on skin, gut and lung specimens. Double immunostaining was performed with anti-CCR3 and antitryptase, and anti-CCR3 and antichymase antibody (Ab) by using the avidin-biotin-peroxidase system with two different substrates. Mast cells were isolated and purified from humanlung parenchyma (HLMC) by countercurrent elutriation followed by discontinuous Percoll density gradient. Flow-cytometric analysis of HLMC surface CCR3 expression was performed with the monoclonal Ab anti-CCR3 (7B11). Functional activation of HLMC was verified by the ability of cells to release histamine and/or migrate in response to eotaxin. RESULTS: High percentages (>70%) of tryptase-positive cells showing CCR3 expression were found in the skin and in the intestinal submucosa, whereas much lower percentages (< or = 20%) were found in the intestinal mucosa and in the lung interstitium. Eotaxin (1-100 nM) neither induced histamine release from HLMC nor enhanced anti-IgE-induced histamine release. In contrast, eotaxin (10-100 nM) and RANTES (10-100 nM) induced HLMC chemotaxis in vitro. Preincubation of HLMC with antibody anti-CCR3 (5 microg/ml) before loading into the chemotaxis chamber abrogated chemotaxis elicited by eotaxin. Double immunostaining with anti-CCR3 and anti-chymase antibody showed that the vast majority of CCR3-expressing mast cells in the various human tissues examined were tryptase-chymase double-positive. CONCLUSIONS: These results indicate that CCR3 is expressed on human mast cells and that these cells are attracted by CCR3-binding chemokines. Copyright 2001 S. Karger AG, Basel
Authors: Meaghan Roy-O'Reilly; Rodney M Ritzel; Sarah E Conway; Ilene Staff; Gilbert Fortunato; Louise D McCullough Journal: Transl Stroke Res Date: 2017-06-21 Impact factor: 6.829
Authors: Carine Blanchard; Ning Wang; Keith F Stringer; Anil Mishra; Patricia C Fulkerson; J Pablo Abonia; Sean C Jameson; Cassie Kirby; Michael R Konikoff; Margaret H Collins; Mitchell B Cohen; Rachel Akers; Simon P Hogan; Amal H Assa'ad; Philip E Putnam; Bruce J Aronow; Marc E Rothenberg Journal: J Clin Invest Date: 2006-02 Impact factor: 14.808
Authors: Laura S Van Winkle; Gregory L Baker; Jackie K W Chan; Edward S Schelegle; Charles G Plopper Journal: Toxicol Sci Date: 2010-04-19 Impact factor: 4.849
Authors: Weilie Ma; Paul J Bryce; Alison A Humbles; Dhafer Laouini; Ali Yalcindag; Harri Alenius; Daniel S Friend; Hans C Oettgen; Craig Gerard; Raif S Geha Journal: J Clin Invest Date: 2002-03 Impact factor: 14.808
Authors: Weisong Zhou; Jian Zhang; Kasia Goleniewska; Daniel E Dulek; Shinji Toki; Dawn C Newcomb; Jacqueline Y Cephus; Robert D Collins; Pingsheng Wu; Mark R Boothby; R Stokes Peebles Journal: J Immunol Date: 2016-07-25 Impact factor: 5.422